Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising ...

Some key growth products include the oncology drug Verzenio and immunology drug Taltz, which accounted for 9% and 6% of total ...

On the dividend front, Eli Lilly and Company (NYSE:LLY) has increased its payout for 11 consecutive years. With a payout ratio of just 44%, the company retains ample room for further dividend growth.

Eli Lilly is a leader in the weight loss drug market, ... Better Growth Buy: Eli Lilly vs. Viking Therapeutics. Adria Cimino, The Motley Fool. July 7, 2025 at 12:45 AM. Copied; Key Points.